No acquisitions were announced at J.P. Morgan this week but Abivax SA could soon find itself the subject of some serious takeover speculation following the French biotech's upbeat presentation at the high-profile healthcare conference centred around its Phase III-ready candidate, ABX464, for chronic inflammatory diseases.
The presentation came hours after EU regulators, just like the US Food and Drug Administration a month earlier, supported the...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?